Skip to main content
Home
  • Global
  • Careers
  • Investors
  • About us
    Fagron company profile

    Activities of Fagron

    Leadership team

    Introduction to members of the Leadership team

    Key figures

    Fagron's key figures in one overview

  • Press
    • Press releases
    • Press kit
  • Publications
    Annual reports

    Please find here our annual reports

    Presentations

    Presentations and conference calls

    Statutory annual accounts

    Please find here the statutory annual accounts

    Prospectus September 2007

    Prospectus of the Initial Public Offering

    Prospectus June 2012

    Prospectus of the 4.75% bond

    Prospectus June 2016

    Prospectus of the capital increase

    Bond

    Compliance certificates and guarantor lists

  • Share
    Share performance

    Look at the actual share performance

    Notification of shareholdings

    Shareholding declaration obligation 

    Dividend

    Dividend policy of Fagron

    Shareholders' meetings

    Documents relating to shareholders' meetings

    Analyst coverage

    Analysts covering Fagron

    Shareholder structure

    Overview of participations

  • Events
    Calendar

    Upcoming events

  • Corporate Governance
    Board of Directors

    Members of the Fagron's Board of Directors

    Leadership team

    Introduction to members of the Leadership team

    Governance documents

    Corporate governance documents

Search form

Go to share performance
  • Shareholders
Back to overview
Print Friendly and PDF
Share by mail

Fagron publishes 2022 ESG targets

13 January 2022

Nazareth (Belgium)/Rotterdam (The Netherlands), 13 January 2022 – 9:30AM CET

Fagron publishes 2022 ESG targets

Corporate social responsibility is at the heart of Fagron's operations and strategy. Fagron's products and services contribute every day to improving the health of people worldwide. Fagron strives to:

  • reduce its impact on the environment;
  • provide products that meet all relevant quality and safety standards;
  • provide benefit to its people;
  • take responsibility in the supply chain; and
  • give back to the communities in which Fagron operates.

To give concrete expression to this aspiration, Fagron is publishing its ESG objectives for 2022.

In addition to the previously defined targets for reducing the greenhouse gas intensity of Fagron's operations, Fagron also sets itself the objective in its 2022 ESG plan, among others, to purchase 50% of its electricity from renewable sources by 2025 and to separate waste at all its locations. In terms of gender equality, Fagron aims not only to have a 50/50 gender distribution of all its staff, but by 2025 also at management level. Furthermore, Fagron wants at least 75% (in purchasing value) of its suppliers to have accepted the Fagron Business Partner Code of Conduct by 2025. The full 2022 ESG plan of Fagron, including all targets can be read on our website.

Rafael Padilla, CEO of Fagron: "Corporate social responsibility is at the heart of what we do: by personalizing medicine, they become accessible to even more people. In 2021 we presented our ESG strategy and reported extensively on our social responsibility for the first time in our 2020 annual report. Since then, we have made some important steps, such as a significant reduction in the greenhouse gas intensity of our operations (scope 1, 2 and business travel) and an increase in the number of annual performance and development reviews of our employees to 85%. However, we must continue to develop ourselves. Fagron is thus constantly adapting its ESG strategy in response to developments in the ESG field, trends in the sector and regions where we operate, and the input we receive from our stakeholders. I am proud that we have again set ourselves challenging targets for 2022 to make our contribution to a better world."

Fagron endorses all 17 Sustainable Development Goals (SDGs) defined by the United Nations in 2015. Based on the defined sustainability strategy, Fagron has selected five categories where it actively focuses and where it believes it can make the highest contribution: environment, our people, supply chain responsibility, giving back and good governance.

Further information

Karen Berg Sanne Nusselder
Global Investor Relations Manager Global ESG Manager
Tel. +31 6 53 44 91 99         Tel.: +31 6 22 58 26 65
[email protected] [email protected]

About Fagron
Fagron is a leading global company active in pharmaceutical compounding, focusing on delivering personalized medicine to hospitals, pharmacies, clinics and patients in 35 countries around the world.

Belgian company Fagron NV has its registered office in Nazareth and is listed on Euronext Brussels and Euronext Amsterdam under the ticker symbol ‘FAGR’. Fagron’s operational activities are managed by the Dutch company Fagron BV, which is headquartered in Rotterdam.

Important information regarding forward-looking statements
Certain statements in this press release may be deemed to be forward-looking. Such forward-looking statements are based on current expectations and are influenced by various risks and uncertainties. Consequently, Fagron cannot provide any guarantee that such forward-looking statements will, in fact, materialize and cannot accept any obligation to update or revise any forward-looking statement as a result of new information, future events or for any other reason.

In the event of differences between the English translation and the Dutch original of this press release, the latter prevails.

Please open the link below for the press release:
Fagron publishes 2022 ESG targets

Fagron publishes 2022 ESG targets

About Fagron

Fagron is the leading global pharmaceutical compounding company, bringing customized pharmaceutical care to hospitals, pharmacies, clinics and patients in 35 countries worldwide.

Press releases

Sign up to receive our latest press releases.

Subscribe

Contact us

  • +31 (0) 88 33 11 200
  • [email protected]

Contact information

© Copyright 2022 Fagron.

  • Disclaimer
  • Privacy Statement

The Fagron Investor Relations website uses cookies. By visiting this website, or by clicking the ‘Agree’ button on the right you agree with this.  More information.